To appraise the clinical and cost effectiveness of cemiplimab within its marketing authorisation for treating cutaneous squamous cell carcinoma.
Status In progress
Process STA 2018
ID number 1367

Provisional Schedule

Expected publication 03 July 2019

Project Team

Project lead Gemma Barnacle

Email enquiries


Companies sponsors Regeneron Pharmaceuticals and Sanofi (cemiplimab)
Others Department for Health and Social Care
  NHS England
  NHS Herts Valleys CCG
  NHS Telford & Wrekin CCG
  Welsh Government
Patient carer groups Black Health Agency
  British Skin Foundation
  Cancer 52
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients’ Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  Skcin - Karen Clifford Skin Cancer Charity
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  British Association of Dermatologists
  British Association of Skin Cancer Specialist Nurses
  British Dermatological Nursing Group
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Skin Foundation
  British Society for Dermatological Surgery
  Cancer Research UK
  Primary Care Dermatology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord (carboplatin, cisplatin, fluorouracil)
  Almirall (fluorouracil)
  Consilient Health (fluorouracil)
  Pfizer (carboplatin, cisplatin, fluorouracil)
  Medac (fluorouracil)
  Sandoz (cisplatin)
General commentators All Wales Therapeutic and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups British Society for Dermatological Surgery
  Cochrane Skin Group
  Institute of Cancer Research
  MRC Clinical Trials Unit
  Myfanwy Townsend Melanoma Research Fund
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
  Skin Cancer Research Fund
  Skin Treatment & Research Trust


Key events during the development of the guidance:

Date Update
24 August 2018 Invitation to participate
30 April 2018 (13:00) Scoping workshop (London)
01 March 2018 - 29 March 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 March 2018 In progress, Ref from DH received 05.12.17
05 December 2017 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance